Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.
scPharmaceuticals Inc. reports news on its cardiorenal pharmaceutical business, including commercialization of FUROSCIX, furosemide formulation development, and intellectual property for SCP-111. Company updates also cover clinical and regulatory disclosures tied to cardiorenal conditions such as heart failure and chronic kidney disease.
Recurring releases include quarterly financial results, business updates, product revenue trends, material agreements, capital-structure actions, governance matters, investor-conference participation, and corporate-status developments affecting SCPH common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.